On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridayOct 23, 2020 3:09 pm

SPAC Merger Fires Boosters for 180 Life Sciences’ Exploration in Unmet Medical Needs of Anti-inflammatories Space

Biotechnology company 180 Life Sciences has launched a variety of advanced clinical and preclinical-stage efforts to develop novel anti-inflammatory treatments for patients with chronic illnesses A planned merger with 180 Life Sciences advanced under a special purpose acquisition corporation (SPAC) is expected to be completed within the next month, resulting in a Nasdaq filing under the ticker ATNF 180 Life Sciences’s founders are an experienced team of medical scientists who pioneered anti-inflammatory pharmaceuticals in the 1990s that are still in use today, generating billions in revenue The company’s own-IP clinical trials seek to resolve inflammation-related issues in conditions such as…

Continue Reading

FridayOct 23, 2020 2:20 pm

Net Element Inc. (NASDAQ: NETE), Mullen Stand to Benefit from Decreasing EV Manufacturing Costs

Investment bank UBS reports that electric cars will cost the same to make as conventional cars by 2024. Expensive batteries, which account for between a quarter and two-fifths of EV’s cost, have been barrier to production. NETE recently announced entry into EV space through merger with privately held Mullen Technologies Inc. New research from investment bank UBS indicates that electric vehicles (“EVs”) may be as cheap to manufacture as regular models within the next four years (https://nnw.fm/gPsnf). This news bodes well for Net Element Inc. (NASDAQ: NETE), a global financial technology and value-added solutions group that recently announced its planned…

Continue Reading

FridayOct 23, 2020 2:01 pm

Fast-Growing Michigan Market Next in Line for Gage Cannabis Co., IPO Planned for 2021

Gage expanding in Michigan, one of fastest-growing legal cannabis markets in United States Adult-use cannabis revenues in Michigan projected at $1 billion per year for 2021, surpassing $1.5 billion by 2023 Gage currently operates 5 dispensaries, planning to open and operate 8-10 by the end of 2020, with 20+ expected to open by the end of 2021 YTD revenue estimated at $30+ million, 157% increase from January to September 2020 Gage planning Canadian listing for Q1 2021 Bruce Linton, a pioneer of the global cannabis industry and current executive chairman of Gage Cannabis Co., has set his sights on Michigan…

Continue Reading

FridayOct 23, 2020 1:30 pm

Pure Extract Technologies Inc.’s Three-Pillar Business Model Points Company Toward Success

‘Harvard Business Review’ cites importance of a good business model, specifies key questions it should answer. Pure Extracts’ business model founded on three pillars: extraction services, formulation & white-labeling, and development of its in-house ‘Pure Pulls’ branded cannabis and functional mushroom products. Company’s business model is multi-faceted, comprehensive and allows for future growth. A strong business model is essential to every successful organization, whether it’s a new venture or an established player, touts a “Harvard Business Review” article titled “Why Business Models Matter.” Pure Extracts Technologies Corp., a plant-based extraction company with a new vertical in functional mushrooms, recognizes the…

Continue Reading

FridayOct 23, 2020 1:06 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate Commences

Berubicin Expected to Commence Trials for the Treatment of Glioblastoma, An Aggressive Form of Brain Cancer Currently Considered Incurable Production of Berubicin Begins in the U.S. and Europe Dual Manufacturing Facilities Engaged to Reduce Supply Chain Interruptions IND for Berubicin Could Be Filed by Year End CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) expects to have an Investigational New Drug Application (“IND”) ready for its lead drug candidate, Berubicin, by the end of 2020. An approved IND would give the biotech company, which is developing treatments for primary and metastatic cancers of the brain and central nervous system, the green light to…

Continue Reading

FridayOct 23, 2020 11:37 am

The Wild West Crypto Show Points to Growing Adoption of Cryptocurrencies as an Investment Vehicle and Liquid Form of Money

Wild West Crypto Show hosts Drew Taylor and Brent Bates delivered a strong dose of Texas-flavored evangelical and political fervor in episode 130 of their popular multi-platform broadcast for educating potential investors about the benefits and hazards of the cryptocurrency market. Comments applied to the show’s news segment as well, in which the hosts and contributing analyst Jonathan Keim, the communications director of CryptoCurrencyWire, noted research showing growing adoption of cryptocurrencies, not just as an investment vehicle but as a liquid form of money. “The fact that 70% of the 35,000 respondents are now spending crypto, and not just HODLing…

Continue Reading

ThursdayOct 22, 2020 9:58 am

Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise

Cybin appoints health-care expert Doug Drysdale as new CEO. Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships. New CEO says business model, talented management team positions company to examine new psychedelic-based therapies, delivery systems. Cybin Corp.,a life sciences company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://nnw.fm/wPyaa). Drysdale brings more than three decades of experience in the health-care sector and will continue to grow its IP portfolio. “With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and COO Paul Glavine.…

Continue Reading

ThursdayOct 22, 2020 9:44 am

The JBoy Show Talks with Sportswriter Woody Paige

Woody Paige shares memories of growing up as Elvis Presley’s neighbor Tom Brady appears to be nearing end of his NFL career COVID has put temporary end to tailgating Sportswriter and ESPN’s Around the Horn host Woody Paige joined Jake Crain on The JBoy Show’s Sept. 15 episode to discuss Elvis Presley, coaches, tailgating and more. The show began with Paige reminiscing about his childhood when he was the next-door neighbor to Elvis Presley in government housing. He used to sit on the front porch and listen to Presley play guitar, Paige shared. Once he got older, he even joined…

Continue Reading

ThursdayOct 22, 2020 9:24 am

InsuraGuest Technologies, Inc. (TSX.V: ISGI) Proprietors Policy Portal Now Open for Business

Launch of InsurTech Portal to Offer Business Owner Liability Protection The Insure the People Portal to Provide Coverage to Over 130 Class Codes Coverage for Building & Business Property and Business Income General Liability Occurrence Limits: US$300,000, US$500,000, US$1 million and US$2 million Employment Practices Liability With the launch of its business owner policy (“BOP”) portal, InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: IGSTF) is extending its general liability coverage to a vital sector of the U.S. economy: small businesses. Through the site—InsureThePeople.com—small business owners and operators of a wide range of enterprises, from public accountants to commodity merchants to bars…

Continue Reading

ThursdayOct 22, 2020 9:00 am

In Pursuit of the Elusive Drug — the Billion-Dollar Blockbuster

NetworkNewsWire Editorial Coverage: Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug. While the discovery of a blockbuster drug, or a drug that generates more than $1 billion in sales per year, occurs rarely, the tremendous benefits of owning blockbuster therapeutics can mean tens of billions of dollars for a company during the patent-protected life of the drug. It makes sense, then, that pharmaceutical giants are in hot pursuit of what could be the next new drug — and the company that owns…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217